A Phase 2 Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects With Mac-off Retinal Detachment
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- ONL Therapeutics
- Study ID
- NCT05730218
- Phase
- PHASE2
- Status
- Completed
Conditions
- Rhegmatogenous Retinal Detachment - Macula Off
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- ONL1204 Ophthalmic Solution — DRUGONL1204 Ophthalmic Solution at one of two doses delivered via intravitreal injection
- Sham treatment — DRUGSham injection is performed by touching the eye surface with a syringe without a needle
Study Details
The goal of this Phase 2 clinical trial is to learn about ONL1204 Ophthalmic Solution in terms of safety and how well the drug works in patients that have a macula-off (central point of vision) rhegmatogenous retinal detachment (RRD). The main questions it aims to answer are: * Does ONL1204 improve vision in macula-off RRD patients when used before retinal detachment repair surgery compared to patients that have surgery alone? * Is ONL1204 safe to use as an add-on drug before retinal repair surgery? Researchers will observe patients that receive two different dosages of ONL1204 Ophthalmic Solution (50 µg or 200 µg) compared to current standard therapy (no treatment) to see if there are differences in vision and safety outcomes.
Key Dates
- First listed
- Feb 15, 2023
- Start date
- Apr 4, 2023
- Status verified
- Feb 2024
- Primary completion
- Feb 21, 2024
- Completion
- Feb 21, 2024
Study Design
- Enrollment
- 136 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment Group AONL1204 Ophthalmic Solution Dose A administered by intravitreal injection
- Experimental: Treatment Group BONL1204 Ophthalmic Solution Dose B administered by intravitreal injection
- Sham Comparator: Treatment Group CSham injection is performed by touching the eye surface with a syringe without a needle
Primary Outcome Measure
Mean area under the log contrast sensitivity function (AULCSF) [ Time Frame: Week 24 ]